Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis (Q38174167)

30 August 2017

title

Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis (English)

1 reference

primary sclerosing cholangitis

30 August 2017

main subject

ascending cholangitis

0 references

1 reference

based on heuristic

inferred from title

primary biliary cholangitis

0 references

1

T H Karlsen

1 reference

30 August 2017

3

K M Boberg

1 reference

30 August 2017

M Vesterhus

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

29 December 2013

1 reference

Alimentary Pharmacology & Therapeutics

30 August 2017

published in

1 reference

30 August 2017

volume

39

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

282-301

1 reference

Molecular pathogenesis of cholestasis.

30 August 2017

cites work

1 reference

Genetics of cholestatic liver disease in 2010.

21 January 2018

1 reference

Bile acid transporters and regulatory nuclear receptors in the liver and beyond

21 January 2018

1 reference

Pathogenesis of Cholestatic Liver Disease and Therapeutic Approaches

21 January 2018

1 reference

The genetics of complex cholestatic disorders

21 January 2018

1 reference

A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis

21 January 2018

1 reference

A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis

21 January 2018

1 reference

Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease

21 January 2018

1 reference

Novel insights into autoimmune liver diseases provided by genome-wide association studies

21 January 2018

1 reference

Gallstone disease: from genes to evidence-based therapy

21 January 2018

1 reference

Congenital cholestatic syndromes: what happens when children grow up?

21 January 2018

1 reference

The immunobiology and pathophysiology of primary biliary cirrhosis

21 January 2018

1 reference

New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies.

21 January 2018

1 reference

Overcoming a "probable" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature

21 January 2018

1 reference

Detection of novel non-M2-related antimitochondrial antibodies in patients with anti-M2 negative primary biliary cirrhosis.

21 January 2018

1 reference

Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis

21 January 2018

1 reference

Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis

21 January 2018

1 reference

Antimitochondrial antibody-negative primary biliary cirrhosis

21 January 2018

1 reference

Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)?

21 January 2018

1 reference

A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults

21 January 2018

1 reference

The natural history of small-duct primary sclerosing cholangitis

21 January 2018

1 reference

Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis.

21 January 2018

1 reference

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

21 January 2018

1 reference

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid

21 January 2018

1 reference

Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines

21 January 2018

1 reference

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

21 January 2018

1 reference

Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid

21 January 2018

1 reference

Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis

21 January 2018

1 reference

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis

21 January 2018

1 reference

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid

21 January 2018

1 reference

Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis

21 January 2018

1 reference

Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis

21 January 2018

1 reference

Primary biliary cirrhosis and bile acids

21 January 2018

1 reference

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

21 January 2018

1 reference

PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide

21 January 2018

1 reference

Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone

21 January 2018

1 reference

Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial

21 January 2018

1 reference

Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis

21 January 2018

1 reference

Towards common denominators in primary biliary cirrhosis: the role of IL-12

21 January 2018

1 reference

Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants

21 January 2018

1 reference

Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population

21 January 2018

1 reference

Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update

21 January 2018

1 reference

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

Infectious agents and xenobiotics in the etiology of primary biliary cirrhosis

21 January 2018

1 reference

Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid

21 January 2018

1 reference

Triggers and drivers of autoimmunity: lessons from coeliac disease

21 January 2018

1 reference

Effects of long-term rifampicin administration in primary biliary cirrhosis

21 January 2018

1 reference

Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

21 January 2018

1 reference

Primary biliary cirrhosis

21 January 2018

1 reference

Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence

21 January 2018

1 reference

Quality of life before and after liver transplantation for cholestatic liver disease

21 January 2018

1 reference

The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort.

21 January 2018

1 reference

Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis

21 January 2018

1 reference

Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers.

21 January 2018

1 reference

Screening for liver cancer: the rush to judgment

21 January 2018

1 reference

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

Recurrent primary biliary cirrhosis after liver transplantation

21 January 2018

1 reference

Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation

21 January 2018

1 reference

Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant

21 January 2018

1 reference

Liver transplantation in PBC and PSC: indications and disease recurrence

21 January 2018

1 reference

Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients.

21 January 2018

1 reference

Epidemiology of primary sclerosing cholangitis

21 January 2018

1 reference

Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis

21 January 2018

1 reference

Mucosal immunity in liver autoimmunity: a comprehensive review

21 January 2018

1 reference

Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease.

21 January 2018

1 reference

Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis--overlapping or separate diseases?

21 January 2018

1 reference

IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis.

21 January 2018

1 reference

What an endoscopist should know about immunoglobulin-G4-associated disease of the pancreas and biliary tree

21 January 2018

1 reference

Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related sclerosing cholangitis: a Japanese cohort.

21 January 2018

1 reference

Mucosal IgG4 cell infiltration in ulcerative colitis is linked to disease activity and primary sclerosing cholangitis

21 January 2018

1 reference

Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma

21 January 2018

1 reference

Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy

21 January 2018

1 reference

Diagnosis and management of primary sclerosing cholangitis.

21 January 2018

1 reference

Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis

21 January 2018

1 reference

Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis.

21 January 2018

1 reference

Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study

21 January 2018

1 reference

Primary sclerosing cholangitis and malignancy

21 January 2018

1 reference

Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

21 January 2018

1 reference

Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis

21 January 2018

1 reference

Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis

21 January 2018

1 reference

Gallbladder polyps in primary sclerosing cholangitis: not so benign

21 January 2018

1 reference

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis

21 January 2018

1 reference

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective

21 January 2018

1 reference

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

21 January 2018

1 reference

High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?

21 January 2018

1 reference

Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis

21 January 2018

1 reference

Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis

21 January 2018

1 reference

Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis

21 January 2018

1 reference

Differential effects of norUDCA and UDCA in obstructive cholestasis in mice

21 January 2018

1 reference

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice

21 January 2018

1 reference

New treatment strategies for primary sclerosing cholangitis

21 January 2018

1 reference

Modulation of the fecal bile acid profile by gut microbiota in cirrhosis

21 January 2018

1 reference

Host-gut microbiota metabolic interactions

21 January 2018

1 reference

Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases.

21 January 2018

1 reference

Update on primary sclerosing cholangitis

21 January 2018

1 reference

Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC.

21 January 2018

1 reference

ARFI elastography in patients with chronic autoimmune liver diseases: A preliminary study

21 January 2018

1 reference

Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis

21 January 2018

1 reference

Long-term immunosuppression for prevention of nonviral disease recurrence

21 January 2018

1 reference

Recurrence and rejection in liver transplantation for primary sclerosing cholangitis

21 January 2018

1 reference

Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC.

21 January 2018

1 reference

Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease.

21 January 2018

1 reference

Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens

21 January 2018

1 reference

Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue

21 January 2018

1 reference

Simplified criteria for the diagnosis of autoimmune hepatitis

21 January 2018

1 reference

Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome

21 January 2018

1 reference

Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival

21 January 2018

1 reference

Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome

21 January 2018

1 reference

The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies

21 January 2018

1 reference

Bile acids: natural ligands for an orphan nuclear receptor

21 January 2018

1 reference

Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity

21 January 2018

1 reference

Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis

21 January 2018

1 reference

21 January 2018

TGR5 in cholangiocytes

1 reference

The itch of liver disease

21 January 2018

1 reference

Pruritus in cholestasis: facts and fiction.

21 January 2018

1 reference

Lysophosphatidic acid is a potential mediator of cholestatic pruritus

21 January 2018

1 reference

The TGR5 receptor mediates bile acid-induced itch and analgesia

21 January 2018

1 reference

Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease

21 January 2018

1 reference

The true impact of fatigue in primary biliary cirrhosis: a population study

21 January 2018

1 reference

Impact of fatigue on the quality of life of patients with primary biliary cirrhosis.

21 January 2018

1 reference

Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study

21 January 2018

1 reference

The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: Results of a 9year follow-up

21 January 2018

1 reference

Screening for hepatocellular carcinoma: The rationale for the American Association for the Study of Liver Diseases recommendations

21 January 2018

1 reference

FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.12581

1 reference

30 August 2017

1 reference